PMC9273879_01
PMC9273879_02
Time-course of immunosuppression therapy during the course of patient treatment from UTx through to embryo transfer. OR, oral; UTx, Uterus Transplantation; ET, Embryo Transfer; d, day.
fsurg-09-854225-g001.jpg
PMC9273879_02_fsurg-09-854225-g001.jpg
F1
Administration of immunosuppression therapies are summarized in Figure 1.
Creatinine and tacrolimus concentrations from the day before UTx until day 6 post-partum. d: day; m: month; w: week of gestation; pp: post-partum. Blue lines represent objective levels of residual tacrolimus level (8-12 ng/mL during the first month, 7-10 ng/mL during the second and third month, and then 5-8 ng/mL).
fsurg-09-854225-g002.jpg
PMC9273879_02_fsurg-09-854225-g002.jpg
F2
Creatinine concentrations increased during pregnancy; serum tacrolimus concentrations tended to decrease during the first trimester requiring a doubling in dose thereafter (Figure 2).
Timeline of clinical presentation and medications during pregnancy and post-partum hospitalization. HBP, High blood pressure; OR, oral; -ve, negative; +ve, positive.
fsurg-09-854225-g003.jpg
PMC9273879_02_fsurg-09-854225-g003.jpg
F3
Her medications and clinical presentation during hospitalization are summarized in Figure 3. Acute renal failure and high blood pressure resolved 1 and 3 weeks, respectively, after delivery (Figure 3).